Creating a Global Company

Our Specialty Pipeline 10 SUN PHARMA Route of Mechanism of Molecule/Asset Indication Pre-clinical Phase-1 Phase-2 Phase-3 Registration Approved Administration Action Ilumya Psoriatic IL-23 Injection (tildrakizumab) Arthritis Antagonist Psoriasis, Selective SIPR1 SCD-044 Atopic Dermatitis Oral Agonist MM-II Treatment of pain in osteoarthritis Liposomal intra Injection -articular lubrication GL0034 Type 2 Diabetes Injection GLP-1R Agonist 10 Creating Lasting Value - Investor Presentation

View entire presentation